Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Protalix BioTherapeutics (PLX) Reports Q3 Revenues Beat
October 29, 2020 7:50 AM EDTProtalix BioTherapeutics (NYSE: PLX) reported Q3 revenue for the quarter came in at $10.8 million versus the consensus estimate of $10.08 million.
Third Quarter 2020 Financial Highlights
The Company recorded revenues from selling goods of $3.3 million during the three months ended September 30, 2020, a decrease of $1.8 million, or 36%, compared to revenues of $5.1 million for the same period of 2019. The decrease resulted primarily from a timing difference in sales to Brazil in 2020... More